Friday, July 10, 2026

pharma · Mantle Cell Lymphoma · Colon cancer

Telethon Foundation

Fondazione Telethon ETS is a pharma organization headquartered in EU. Primary therapeutic focus areas include Mantle Cell Lymphoma, Colon cancer, colorectal cancer, NSCLC non-small cell lung cancer, Follicular lymphoma.

roma, IT HQ
1990 Founded
343 Employees
EMA registrant Type
Company details
Status
Public
HQ
roma, IT
Founded
1990
Employees
343
Programs
162
Drugs
285
Patents
0
Clinical program

ABEMACICLIB , RO7197597

Phase 2 · small molecule · ER-positive, HER2-negative Early breast cancer

ABEMACICLIB , RO7197597 for ER-positive, HER2-negative Early breast cancer is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

← All Fondazione Telethon ETS projects Phase 2 small molecule active

Internal code GIM31-Neo-AGILE

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Fondazione Telethon ETS
Phase
Phase 2
Modality
small_molecule
Indication
ER-positive, HER2-negative Early breast cancer
Status
active
Trials
1